Treatment with a new dual cell cycle and angiogenesis pathway inhibitor blocks VEGF-induced vascular permeability, inhibits tumour angiogenesis and induces apoptosis in human tumour models said Dr. Gerhard Siemeister of Schering AG, Corporate Research, Berlin speaking at the 18th meeting of the European Association of Cancer Research.
Loss of cell cycle control (runaway growth) and tumour-induced angiogenesis (development of new blood vessels to supply the growing tumour with oxygen) are two major hallmarks of cancer. Loss of cell cycle control as a consequence of aberrant cyclin-dependent kinase (CDK) control has been directly linked to the molecular pathology of cancer. CDK's are a family of enzymes required for the correct timing and order of events in the cell division cycle. Vascular endothelial growth factor (VEGF) / VEGF-receptor tyrosine kinase (VEGF-RTK) and platelet-derived growth factor (PDGF)-RTKs are two molecules known to be involved in tumour angiogenesis.
The new compound, called 'ZK-CDK', is a novel, chemically synthesized small molecule ATP-competitive kinase inhibitor that is unique in that combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule.